DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

Information source: Crucell Holland BV
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rabies

Intervention: Rabies virus-specific monoclonal antibodies (Biological); human polyclonal rabies immune globulin (HRIG) (Biological); Placebo (Biological); Human diploid cell vaccine (HDCV) (Biological); Purified verocell rabies vaccine (PVRV) (Biological)

Phase: Phase 2

Status: Completed

Sponsored by: Crucell Holland BV

Official(s) and/or principal investigator(s):
G Nagashayana, MD, Principal Investigator, Affiliation: Lotus Labs Pvt. Ltd, Bangalore, India

Summary

Study design: Single-blind (subject and observer-blinded), active-controlled, randomized [6: 2:1: 2:1; CL184 + purified vero cell rabies vaccine (PVRV) vs. human rabies immune globulin (HRIG) + PVRV vs. placebo + PVRV vs. CL184 + human diploid cell vaccine (HDCV) vs. placebo + HDCV], mono-center study Study objectives: Primary: To evaluate the safety of CL184 in combination with PVRV in healthy adult subjects. Secondary: To evaluate the safety of HRIG or placebo in combination with PVRV and to evaluate the safety of CL184 or placebo in combination with HDCV in healthy adult subjects. To evaluate the rabies virus neutralizing activity (RVNA) after administration of CL184 or placebo in combination with PVRV, of HRIG in combination with PVRV, and of CL184 or placebo in combination with HDCV in healthy adult subjects. To evaluate the pharmacokinetics of the monoclonal antibodies (mAbs).

Clinical Details

Official title: A Randomized, Single-blind, Active-controlled, Mono-center Phase II Study to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Purified Vero Cell Rabies Vaccine vs. Human Rabies Immune Globulin or Placebo in Combination With Purified Vero Cell Rabies Vaccine vs. CL184 or Placebo in Combination With Human Diploid Cell Rabies Vaccine in Healthy Adult Subjects

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: Number of participants with adverse events as a measure of safety

Secondary outcome: Rabies virus neutralizing activity

Detailed description: This study was designed to explore and obtain further safety and RVNA data on CL184 in comparison to HRIG and placebo as part of a classical post-exposure prophylaxis (PEP) regimen. This regimen will be applied as simulated PEP regimen to healthy subjects (i. e. in a pre-exposure setting) in this study. A comparison with placebo combined with each rabies vaccine was included to differentiate between the contribution of immune globulin and vaccine and to investigate potential interactions between immune globulin and vaccine. RVNA provided by CL184 or HRIG, as well as vaccination response will be checked regularly during the study and booster doses can be applied after the study, if necessary. In addition pharmacokinetic data will be collected.

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female subject aged ≥18 to ≤55 years

- Subjects free of obvious health-problems or with stable conditions or medications

- Body mass index between ≥18 to ≤30 kg/m2

- Abstinence from sexual intercourse or use of adequate contraception from the date of

screening up to Day 90

- Male subjects must agree that they will not donate sperm from the first check-in

until Day 90

- Subject signed written informed consent

Exclusion Criteria:

- Prior history of active or passive rabies immunization

- Clinically significant acute illness or infection including fever (≥38 °C) within 2

weeks before first dosing

- History and/or family history of clinically significant immunodeficiency or

auto-immune disease

- Planned immunization with live vaccines during the coming 3 months after first dosing

- Chronic (longer than 14 days) administration of immunosuppressants or other

immune-modifying drugs within 6 months before the first dose of investigational medicinal product

Locations and Contacts

Lotus House, Vasanth Nagar, Bangalore, Karnataka 560 052, India
Additional Information

Starting date: December 2011
Last updated: April 3, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017